Last reviewed · How we verify
Cephalosporins and Macrolide Antibiotics
Cephalosporins and Macrolide Antibiotics is a Small molecule drug developed by Beijing Children's Hospital. It is currently in Phase 2 development. Also known as: azithromycin, erythromycin, cefamandole, latamoxef.
At a glance
| Generic name | Cephalosporins and Macrolide Antibiotics |
|---|---|
| Also known as | azithromycin, erythromycin, cefamandole, latamoxef, ceftriaxone |
| Sponsor | Beijing Children's Hospital |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
- Urethral Discharge
- NICU admission
- Blood Pressure Increased
- Dysuria
- Vomitting
- Postpartum preeclampsia/readmission
- Headache
- Glycosuria
- Urethritis
- Diarrhoea
- Instillation Site Pain
- Myalgia
Key clinical trials
- Testing a Novel Combination Treatment (Arm D) Versus Standard of Care for Intensive Phase Treatment for Mycobacterium Abscessus Pulmonary Disease in People With or Without Cystic Fibrosis in the Finding the Optimal Regimen for Mycobacterium Abscessus Treatment (FORMaT) Adaptive Platform Trial (PHASE2)
- Antibiotic Prophylaxis to Prevent Obesity-Related Induction Complications in Nulliparae at Term 2.0 (PHASE2)
- Assessing Role of Probiotics in Children Aged 6-36 Months Treated for Pneumonia (NA)
- Improvement of PPROM Management With Prophylactic Antimicrobial Therapy (iPROMPT) (PHASE4)
- Clarithromycin Treatment to Prevent Sepsis Progression in CAP (REACT) (PHASE3)
- Finding the Optimal Regimen for Mycobacterium Abscessus Treatment (PHASE2, PHASE3)
- Nasal Iodine Swab Versus Oral Antibiotic to Prevent Surgical Site Infection After Undergoing Mohs Micrographic Surgery (NA)
- Urogenital Infections in Women of Reproductive Age and the Activity of 4-Thiazolidinone Derivatives Against Pathogens (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Cephalosporins and Macrolide Antibiotics CI brief — competitive landscape report
- Cephalosporins and Macrolide Antibiotics updates RSS · CI watch RSS
- Beijing Children's Hospital portfolio CI
Frequently asked questions about Cephalosporins and Macrolide Antibiotics
What is Cephalosporins and Macrolide Antibiotics?
Cephalosporins and Macrolide Antibiotics is a Small molecule drug developed by Beijing Children's Hospital.
Who makes Cephalosporins and Macrolide Antibiotics?
Cephalosporins and Macrolide Antibiotics is developed by Beijing Children's Hospital (see full Beijing Children's Hospital pipeline at /company/beijing-children-s-hospital).
Is Cephalosporins and Macrolide Antibiotics also known as anything else?
Cephalosporins and Macrolide Antibiotics is also known as azithromycin, erythromycin, cefamandole, latamoxef, ceftriaxone.
What development phase is Cephalosporins and Macrolide Antibiotics in?
Cephalosporins and Macrolide Antibiotics is in Phase 2.
What are the side effects of Cephalosporins and Macrolide Antibiotics?
Common side effects of Cephalosporins and Macrolide Antibiotics include Urethral Discharge, NICU admission, Blood Pressure Increased, Dysuria, Vomitting, Postpartum preeclampsia/readmission.
Related
- Manufacturer: Beijing Children's Hospital — full pipeline
- Also known as: azithromycin, erythromycin, cefamandole, latamoxef, ceftriaxone
- Compare: Cephalosporins and Macrolide Antibiotics vs similar drugs
- Pricing: Cephalosporins and Macrolide Antibiotics cost, discount & access